Home > Riviste > Minerva Biotechnology and Biomolecular Research > Fascicoli precedenti > Minerva Biotecnologica 2003 June;15(2) > Minerva Biotecnologica 2003 June;15(2):153-60

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Share

 

ORIGINAL ARTICLES  TRENDS IN MOLECULAR DIAGNOSIS AND THERAPY OF β-THALASSEMIA AND SICKLE CELL ANEMIA 

Minerva Biotecnologica 2003 June;15(2):153-60

Copyright © 2003 EDIZIONI MINERVA MEDICA

lingua: Inglese

Use of macroarray technology to study the effects of DNA-binding drugs on gene expression profile of erythroid-induced human leukemic K562 cells

Mischiati C. 1, Sereni A. 1, Gambari R. 1, 2

1 Department of Biochemistry and Molecular Biology, University of Ferrara, Ferrara, Italy; 2 Biotechnology Center, University of Ferrara, Ferrara, Italy


PDF


In ­this ­paper, we ­review ­recent ­data ­obtained in our labor­a­to­ry, ­aimed to deter­mine the ­effects of DNA-bind­ing mole­cules on ­gene expres­sion pro­file and their abil­ity to ­induce dif­fe­ren­ti­a­tion in K562 ­cells and HbF pro­duc­tion in eryth­roid pre­cur­sor ­cells iso­lat­ed ­from the periph­er­al ­blood of nor­mal ­donors as ­well as tha­las­se­mia ­patients. Here, we ­focused the atten­tion on the molec­u­lar ­effects of tal­li­mus­tine, a DNA bind­ing ­drug ­with selec­tiv­ity for AT sequenc­es ­that was dem­on­strat­ed to ­induce eryth­roid dif­fe­ren­ti­a­tion of ­human K562 leu­ke­mia ­cells as ­well as HbF pro­duc­tion in eryth­roid pre­cur­sor ­cells. By ­using mac­ro­ar­ray tech­nol­o­gy, we iden­ti­fied up- and ­down-reg­u­lat­ed ­genes fol­low­ing treat­ment of K562 ­cells ­with tal­li­mus­tine. These ­results ­were con­firmed by ­reverse-tran­scrip­tion poly­me­rase-­chain reac­tion (RT-PCR) anal­y­sis. Molecular anal­y­sis of the pro­mot­er of ­these ­genes, of the sequenc­es of the mRNA(s), of the struc­ture of the encod­ed pro­tein ­will ­allow to ­design ­decoy ODN, anti­sense DNA or RNA, pep­tides or mono­clo­nal anti­bod­ies expect­ed to mim­ick the bio­log­i­cal ­effects of the ­employed induc­er, lim­it­ing at the ­same ­time pos­sible ­side ­effects.

inizio pagina